MX2022012957A - Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. - Google Patents
Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer.Info
- Publication number
- MX2022012957A MX2022012957A MX2022012957A MX2022012957A MX2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A MX 2022012957 A MX2022012957 A MX 2022012957A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- rho kinase
- preferred
- disease
- kinase inhibitors
- Prior art date
Links
- 239000003590 rho kinase inhibitor Substances 0.000 title abstract 3
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- NGOGFTYYXHNFQH-UHFFFAOYSA-N fasudil Chemical compound C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 NGOGFTYYXHNFQH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002435 fasudil Drugs 0.000 abstract 1
- 208000027061 mild cognitive impairment Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063014272P | 2020-04-23 | 2020-04-23 | |
| PCT/US2021/012588 WO2021216139A1 (en) | 2020-04-23 | 2021-01-08 | Methods of using rho kinase inhibitors to treat alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012957A true MX2022012957A (es) | 2022-11-09 |
Family
ID=78269840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012957A MX2022012957A (es) | 2020-04-23 | 2021-01-08 | Metodos de uso de inhibidores de la quinasa rho para tratar la enfermedad de alzheimer. |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US12329761B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4138842A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2023523706A (cg-RX-API-DMAC7.html) |
| CN (1) | CN115996728A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3175183A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2022012957A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021216139A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11642352B2 (en) * | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| WO2023097151A1 (en) | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
| CN115998736B (zh) * | 2023-03-28 | 2023-06-23 | 中国人民解放军军事科学院军事医学研究院 | Y-27632在特异性抑制幻觉作用中的应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005117896A1 (de) | 2004-06-03 | 2005-12-15 | Schering Aktiengesellschaft | Formulierungen, die fasudil, eine matrix und einem mantel enthalten |
| US20060212090A1 (en) * | 2005-03-01 | 2006-09-21 | Functional Neuroscience Inc. | Method of treating cognitive disorders using neuromodulation |
| EP2061314A4 (en) * | 2006-08-10 | 2010-08-04 | Translational Genomics Res Inst | CONNECTIONS TO IMPROVE LEARNING AND MEMORY |
| US20110237600A1 (en) * | 2008-05-12 | 2011-09-29 | Amnestix, Inc. | Compounds for improving learning and memory |
| US20120010196A1 (en) * | 2010-04-02 | 2012-01-12 | Qin Quingyu | Methods of treating neurodegenerative disorders and diseases |
| EP2825175B1 (en) * | 2012-03-12 | 2017-07-26 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | Rho kinase inhibitors for use in treating amyotrophic lateral sclerosis |
| WO2017003466A1 (en) * | 2015-06-30 | 2017-01-05 | University Of South Florida | Conversion of non-neuronal cells into neurons |
| WO2021142183A1 (en) * | 2020-01-09 | 2021-07-15 | Woolsey Pharmaceuticals, Inc | Methods of treating cortical dementia associated wandering |
| US11642352B2 (en) | 2020-03-25 | 2023-05-09 | Woolsey Pharmaceuticals, Inc. | Methods of treating wandering in Lewy dody dementia |
| US12329761B2 (en) * | 2020-04-23 | 2025-06-17 | Woolsey Pharmaceuticals, Inc. | Methods of using rho kinase inhibitors to treat alzheimer's disease |
| US11311553B1 (en) | 2020-10-22 | 2022-04-26 | Woolsey Pharmaceuticals, Inc. | Methods of treating 4-repeat tauopathies |
| WO2023097151A1 (en) * | 2021-11-29 | 2023-06-01 | Woolsey Pharmaceuticals, Inc. | Methods of treating agitation and other dementia-associated behavioral symptoms |
-
2021
- 2021-01-08 US US17/996,812 patent/US12329761B2/en active Active
- 2021-01-08 JP JP2022563366A patent/JP2023523706A/ja active Pending
- 2021-01-08 CA CA3175183A patent/CA3175183A1/en active Pending
- 2021-01-08 EP EP21793029.6A patent/EP4138842A4/en active Pending
- 2021-01-08 CN CN202180043725.7A patent/CN115996728A/zh active Pending
- 2021-01-08 WO PCT/US2021/012588 patent/WO2021216139A1/en not_active Ceased
- 2021-01-08 MX MX2022012957A patent/MX2022012957A/es unknown
-
2023
- 2023-02-28 US US18/175,605 patent/US11771704B1/en active Active
-
2025
- 2025-05-13 US US19/206,355 patent/US20250268911A1/en active Pending
- 2025-12-25 JP JP2025282162A patent/JP2026053635A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230302011A1 (en) | 2023-09-28 |
| EP4138842A1 (en) | 2023-03-01 |
| CA3175183A1 (en) | 2021-10-28 |
| US20230190765A1 (en) | 2023-06-22 |
| CN115996728A (zh) | 2023-04-21 |
| EP4138842A4 (en) | 2024-04-24 |
| JP2026053635A (ja) | 2026-03-25 |
| US12329761B2 (en) | 2025-06-17 |
| JP2023523706A (ja) | 2023-06-07 |
| US11771704B1 (en) | 2023-10-03 |
| US20250268911A1 (en) | 2025-08-28 |
| WO2021216139A1 (en) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022015800A (es) | Metodos de uso de inhibidores de la quinasa rho para tratar demencia vascular. | |
| MX2025012306A (es) | Inhibidores del gen de sarcoma de rata de kirsten (kras) de 2-azabiciclo [2.2.1] heptano | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| CR20240059A (es) | Compuestos tricíclicos como inhibidores de kras. | |
| Schlesinger et al. | Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study | |
| MX2024004444A (es) | Compuestos de quinolina como inhibidores de la proteina del virus de sarcoma de rata kirsten (kras). | |
| ZA202109010B (en) | Compounds and methods for the treatment of covid-19 | |
| MXPA05003550A (es) | Incremento de dosificacion y dosis diaria dividida de anti-depresivos para tratar padecimientos neurologicos. | |
| MX2025005941A (es) | Moduladores de la actividad tnf-\03b1 | |
| SI1456380T1 (sl) | Smad inhibitorji za zdravljenje cns bolezni | |
| MX2024000237A (es) | Arnip que inhibe la expresión del gen angptl3 y uso del mismo. | |
| MX2025014320A (es) | Compuestos nitrogenados aromaticos, metodos de preparacion y usos medicinales | |
| MA69153A1 (fr) | Méthodes de traitement d'une splénomégalie | |
| JP2023523706A5 (cg-RX-API-DMAC7.html) | ||
| MX2022012310A (es) | Metodos para tratar la esclerosis multiple recidivante con un inhibidor de tirosina quinasa de bruton. | |
| UY39673A (es) | Pauta posológica de sotorasib | |
| MX2021009539A (es) | Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina. | |
| Tadros et al. | Anxiety disorders, PTSD and OCD: systematic review of approved psychiatric medications (2008–2024) and pipeline phase III medications | |
| WO2021242844A8 (en) | Grk2 inhibitors and uses thereof | |
| MX2023007150A (es) | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. | |
| CN109069466A (zh) | 5-ht6受体拮抗剂用于治疗阿尔茨海默病伴情感淡漠共病 | |
| Nash et al. | SAT0293 Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study | |
| MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. | |
| Segamarchi et al. | Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes | |
| MX2022010513A (es) | Metodos para tratar esclerosis multiple progresiva primaria usando un inhibidor de tirosina quinasa de bruton. |